Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133688 | 1.00 | GSR (0.35) | GSRRNPEPNFKB1CPB2CA12 | |
| SCHEMBL15529854 | 0.80 | CHRM2 (0.34) | GSRRNPEPNFKB1CPB2 | |
| SCHEMBL3952652 | 0.74 | GSR (0.38) | GSRRNPEPNFKB1CPB2 | |
| SCHEMBL42855 | 0.69 | — | — | |
| SCHEMBL42856 | 0.69 | — | — | |
| SCHEMBL27722441 | 0.67 | GSR (0.43) | GSRRNPEPNFKB1CPB2CA12 | |
| SCHEMBL42857 | 0.67 | — | — | |
| SCHEMBL28972436 | 0.64 | GSR (0.40) | GSRRNPEPNFKB1CPB2CA12 | |
| SCHEMBL10784463 | 0.64 | GSR (0.35) | GSRRNPEPNFKB1CPB2CA12 | |
| SCHEMBL9836643 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319000-B1 | Compositions and methods for eliciting immune or anti-infective responses | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-15 | — | — | US | disclosed |
| US-20020151678-A1 | Prophylaxis and therapy of acquired immunodeficiency syndrome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM. | 2002-10-17 | — | — | US | disclosed |
| US-6265539-B1 | PEPTIDE FOR USE IN VACCINATION AND PREVENTION OF VIRAL INFECTION; FOR KILLING CELLS EXPRESSING PREFERENTIAL VIRAL PROTEIN | THE UNIVERSITY OF TEXAS SYSTEM THE BOARD OF REGENTS | 2001-07-24 | — | — | US | disclosed |
| US-6210873-B1 | SCREENING BY INTRADERMALLY IMMUNIZING ANIMAL WITH SYNTHETIC PEPTIDE, RECOVERING CELLS FROM LYMPH NODES CLOSE TO SITE, DETERMINING WHETHER CELLS CAN LYSE MAJOR HISTOCOMPATIBILITY COMPLEX-MATCHED TARGET CELLS HAVING PEPTIDE ON SURFACE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2001-04-03 | — | — | US | disclosed |
| EP-0671947-B1 | COMPOSITIONS FOR ELICITING CYTOTOXIC T-LYMPHOCYTE RESPONSES AGAINST VIRUSES | UNIV TEXAS (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0968721-A2 | Use of a composition comprising a peptide for the inhibition of HIV | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0671947-A1 | COMPOSITIONS FOR ELICITING CYTOTOXIC T-LYMPHOCYTE RESPONSES AGAINST VIRUSES | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1993010816-A1 | COMPOSITIONS FOR ELICITING CYTOTOXIC T-LYMPHOCYTE RESPONSES AGAINST VIRUSES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-06-10 | — | — | WO | disclosed |
| EP-0491861-A4 | PROPHYLAXIS AND THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME | — | 1992-10-07 | — | — | EP | disclosed |
| US-5128319-A | Prophylaxis and therapy of acquired immunodeficiency syndrome | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0491861-A1 | PROPHYLAXIS AND THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-07-01 | — | — | EP | disclosed |
| WO-1991004045-A1 | PROPHYLAXIS AND THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151678-A1 | Prophylaxis and therapy of acquired immunodeficiency syndrome | SERPINA6, CD4, VSIG8 | GSR 3803/4885RNPEP 159/4885NFKB1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.